CorMedix Inc buy melinda
Start price
30.11.18
/
50%
€5.90
Target price
14.12.18
€10.00
Performance (%)
7.63%
End price
14.12.18
€6.35
Summary
This prediction ended on 14.12.18 with a price of €6.35. With a performance of 7.63%, the BUY prediction by melinda for CorMedix Inc closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CorMedix Inc | 12.500% | 12.500% | 22.172% | -16.923% |
| iShares Core DAX® | 0.476% | -0.039% | 13.342% | 17.330% |
| iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% | 50.534% |
| iShares Nikkei 225® | 1.300% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 0.829% | 0.193% | 29.756% | 43.432% |
Comments by melinda for this prediction
In the thread CorMedix Inc diskutieren
SecteurProduits pharmaceutiques Agenda 11/12 | 16:00 Assemblée générale
CorMedix, Inc. operates as a pharmaceutical and medical device company that seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters.
The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.
Nombre d'employés : 14 personnes.